These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 18752754)

  • 1. [Effect of rosiglitazone in non-alcoholic steatohepatitis associated liver fibrosis].
    Nan YM; Fu N; Yu J
    Zhonghua Gan Zang Bing Za Zhi; 2008 Aug; 16(8):624-5. PubMed ID: 18752754
    [No Abstract]   [Full Text] [Related]  

  • 2. Rosiglitazone prevents nutritional fibrosis and steatohepatitis in mice.
    Nan YM; Fu N; Wu WJ; Liang BL; Wang RQ; Zhao SX; Zhao JM; Yu J
    Scand J Gastroenterol; 2009; 44(3):358-65. PubMed ID: 18991162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The establishment of a novel non-alcoholic steatohepatitis model accompanied with obesity and insulin resistance in mice.
    Cong WN; Tao RY; Tian JY; Liu GT; Ye F
    Life Sci; 2008 May; 82(19-20):983-90. PubMed ID: 18417155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of liver biopsy and serum markers of liver fibrosis in non-alcoholic fatty liver disease.
    Adams LA; Angulo P
    Clin Liver Dis; 2007 Feb; 11(1):25-35, viii. PubMed ID: 17544970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of fibrosis in Asian patients with non-alcoholic steatohepatitis.
    Tsang SW; Ng WF; Wu BP; Chow DA; Li ET; Wong TC
    J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 1):116-21. PubMed ID: 16706822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with non-alcoholic fatty liver disease.
    Suzuki A; Angulo P; Lymp J; Li D; Satomura S; Lindor K
    Liver Int; 2005 Aug; 25(4):779-86. PubMed ID: 15998429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Waist circumference correlates with liver fibrosis in children with non-alcoholic steatohepatitis.
    Manco M; Bedogni G; Marcellini M; Devito R; Ciampalini P; Sartorelli MR; Comparcola D; Piemonte F; Nobili V
    Gut; 2008 Sep; 57(9):1283-7. PubMed ID: 18218674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum adipokine levels predictive of liver injury in non-alcoholic fatty liver disease.
    Lemoine M; Ratziu V; Kim M; Maachi M; Wendum D; Paye F; Bastard JP; Poupon R; Housset C; Capeau J; Serfaty L
    Liver Int; 2009 Oct; 29(9):1431-8. PubMed ID: 19422483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abnormal glucose tolerance is a predictor of steatohepatitis and fibrosis in patients with non-alcoholic fatty liver disease.
    Haukeland JW; Konopski Z; Linnestad P; Azimy S; Marit Løberg E; Haaland T; Birkeland K; Bjøro K
    Scand J Gastroenterol; 2005 Dec; 40(12):1469-77. PubMed ID: 16293559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of steatohepatitis and advanced fibrosis in non-alcoholic fatty liver disease.
    Pagadala M; Zein CO; McCullough AJ
    Clin Liver Dis; 2009 Nov; 13(4):591-606. PubMed ID: 19818307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Non alcoholic steatohepatitis].
    Manero E; Findor JA; Avagnina A; de Elizalde S; Elsner B
    Medicina (B Aires); 1994; 54(6):625-9. PubMed ID: 7658998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review article: the pathogenesis of fibrosis in non-alcoholic steatohepatitis.
    Marra F; Aleffi S; Bertolani C; Petrai I; Vizzutti F
    Aliment Pharmacol Ther; 2005 Nov; 22 Suppl 2():44-7. PubMed ID: 16225472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic syndrome is associated with severe fibrosis in chronic viral hepatitis and non-alcoholic steatohepatitis.
    Tsochatzis E; Papatheodoridis GV; Manesis EK; Kafiri G; Tiniakos DG; Archimandritis AJ
    Aliment Pharmacol Ther; 2008 Jan; 27(1):80-9. PubMed ID: 17919273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Non-alcoholic steatohepatitis: a controversial cause of liver cirrhosis].
    Guilarte López-Mañas J; Bellot García V; Gil Villa MM
    Gastroenterol Hepatol; 1997 Apr; 20(4):217. PubMed ID: 9280618
    [No Abstract]   [Full Text] [Related]  

  • 15. [Serum folic acid activity in fatty liver and alcoholic cirrhosis].
    Laroche C; Navarro J; Cosson A; Grégoire J; Caquet R
    Sem Hop; 1969 Feb; 45(10):633-9. PubMed ID: 4306993
    [No Abstract]   [Full Text] [Related]  

  • 16. Deficiency of inducible nitric oxide synthase exacerbates hepatic fibrosis in mice fed high-fat diet.
    Chen Y; Hozawa S; Sawamura S; Sato S; Fukuyama N; Tsuji C; Mine T; Okada Y; Tanino R; Ogushi Y; Nakazawa H
    Biochem Biophys Res Commun; 2005 Jan; 326(1):45-51. PubMed ID: 15567150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Noninvasive biomarkers for the screening of fibrosis, steatosis and steatohepatitis in patients with metabolic risk factors: FibroTest-FibroMax experience.
    Munteanu M; Ratziu V; Morra R; Messous D; Imbert-Bismut F; Poynard T
    J Gastrointestin Liver Dis; 2008 Jun; 17(2):187-91. PubMed ID: 18568141
    [No Abstract]   [Full Text] [Related]  

  • 18. The effect of the metabolic syndrome, hepatic steatosis and steatohepatitis on liver fibrosis in hereditary hemochromatosis.
    Adams LA; Angulo P; Abraham SC; Torgerson H; Brandhagen D
    Liver Int; 2006 Apr; 26(3):298-304. PubMed ID: 16584391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is the Total Amount as Important as Localization and Type of Collagen in Liver Fibrosis Attributable to Steatohepatitis?
    Karsdal MA; Detlefsen S; Daniels SJ; Nielsen MJ; Krag A; Schuppan D
    Hepatology; 2020 Jan; 71(1):346-351. PubMed ID: 31553813
    [No Abstract]   [Full Text] [Related]  

  • 20. [A quantitative study of the relationship between levels of liver fibrosis markers in sera and fibrosis stages of liver tissues of patients with chronic hepatic diseases].
    Ding XJ; Li SB; Li SZ; Liu HS; Liu B; Xu FM; Gu RW
    Zhonghua Gan Zang Bing Za Zhi; 2005 Dec; 13(12):911-4. PubMed ID: 16381637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.